10-Q: Earth Science Tech Q1 Net Income Plunges 57%

Earth Science Tech, Inc. reported a significant drop in net income for Q1 2025 despite a slight revenue increase, driven by higher operating expenses and lower gross margins.

Summary

• Revenue for the three months ended June 30, 2025, increased slightly to $8,760,190 from $8,568,918 in the prior year period, a 2.23% increase.
• Gross profit decreased by 4.99% to $6,090,775 from $6,410,434, with gross margin declining from 74% to 69%.
• Net income before taxes fell by 57.57% to $456,714 from $1,076,254 in the same period last year.
• Net income attributable to stockholders decreased by 56.79% to $465,039 from $1,076,254.
• Basic and diluted earnings per common share decreased to $0.001 from $0.003.
• Total operating expenses increased by 9.42% to $5,849,144, primarily due to a 1,518% increase in general and administrative expenses and a 200% increase in marketing expenses.
• Cash and cash equivalents decreased to $877,585 as of June 30, 2025, from $1,473,228 as of March 31, 2025.
• Net cash provided by operating activities significantly decreased to $339,376 from $951,185 in the prior year period.
• The company completed acquisitions of Las Villas Health, LLC, Doconsultations, LLC, and an 80% interest in Magnefuse, LLC for a total cash consideration of $440,500, resulting in $345,997 in goodwill.
• An ongoing $5 million share repurchase program is managed by Avenvi, a wholly-owned subsidiary.

Sentiment

Score: 3

Explanation: While revenue saw a modest increase and strategic acquisitions are underway, the significant decline in net income, gross margin, and operating cash flow, coupled with rising operating expenses, indicates a concerning deterioration in profitability and efficiency for the quarter. The high executive compensation structure also raises questions about capital allocation given the current financial performance.

Positives

• Overall revenue increased by 2.23% year-over-year, reaching $8,760,190.
• Significant growth in revenue from Peaks telemedicine platform, increasing to $541,135 from $42,038.
• Successful integration of new acquisitions (Villas Health, Doconsultations, Mister Meds, Magnefuse) contributing new revenue streams.
• Total assets increased to $7,779,453 as of June 30, 2025, from $7,066,721 as of March 31, 2025.
• Stockholders' equity increased to $4,287,276 as of June 30, 2025, from $3,851,111 as of March 31, 2025.
• The company is actively pursuing licensure expansion for its pharmacies (RxCompound and Mister Meds) to offer services nationwide.
• Peaks telemedicine platform has expanded into the veterinary market through the acquisition of Zoolzy.com.

Negatives

• Net income before taxes decreased by 57.57% to $456,714.
• Net income attributable to stockholders decreased by 56.79% to $465,039.
• Gross profit declined by 4.99% to $6,090,775, and gross margin decreased from 74% to 69%.
• Operating expenses increased by 9.42%, with general and administrative expenses surging by 1,518% and marketing expenses by 200%.
• Cash and cash equivalents decreased by $595,643 during the quarter.
• Net cash provided by operating activities significantly decreased to $339,376 from $951,185 in the prior year period.
• The company's cash balance exceeded federally insured limits by approximately $231,054 as of June 30, 2025.

Risks

• The company's cash balance exceeding federally insured limits by approximately $231,054 as of June 30, 2025, exposes it to potential credit risk if the financial institution were to fail.
• The interim operating results for the three months ending June 30, 2025, may not be indicative of operating results expected for the full year, introducing uncertainty.
• The company's forward-looking statements are subject to risks and uncertainties that could cause actual results or events to differ materially from those expressed or implied.

Future Outlook

The company is evaluating the impact of the recently enacted Taxpayer Fairness and Growth Act of 2025, which includes a federal corporate income tax rate reduction from 21% to 19% effective January 1, 2026, expecting a favorable impact on its effective tax rate in fiscal 2026. It continues to pursue nationwide licensure expansion for its RxCompound and Peaks pharmacies and is expanding Mister Meds' licensure. Peaks has also expanded into the veterinary market through the acquisition of Zoolzy.com, and MagneChef is in the process of expanding its product line. The company is also continuing to make process improvement changes in its internal control over financial reporting.

Management Comments

• Salaries expense increased in preparation for the new businesses the company is expanding.
• The increase in general and administrative expenses is mainly attributable to the reclassification of area managers' expenses from professional fees.
• The increase in marketing expenses was contemplated by management as part of the strategic plan to increase sales.
• The decrease in legal and professional fees is mainly attributable to the reclassification of area managers' expenses.
• The 118% increase in interest expense is attributable to the company signing new leases.
• Management believes the company is not exposed to significant credit risk with respect to cash balances, despite exceeding federally insured limits.
• Accounts receivable are expected to be 100% collected within term.
• Management believes that the composition of receivables at year-end is consistent with historical conditions as credit terms and practices and the client base have not changed significantly.
• The company's management, including the CEO and CFO, concluded that disclosure controls and procedures were effective as of June 30, 2025.
• Company management concluded that internal control over financial reporting was reasonably effective as of June 30, 2025, and will continue to improve.

Industry Context

The company operates in the health and wellness sector, specifically in compounding pharmaceuticals, telemedicine, and healthcare services. Its strategy of acquiring and integrating diverse health-related businesses, including a recent expansion into veterinary telemedicine, aligns with broader industry trends towards diversified healthcare offerings and digital health solutions. The focus on compounding pharmacies and telemedicine addresses the growing demand for personalized medicine and accessible healthcare. The real estate development arm supports the physical infrastructure for its healthcare operations, indicating a vertically integrated approach. The overall industry is experiencing consolidation and a push towards more comprehensive patient care models.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• As of June 30, 2025, and March 31, 2025, there were no pending or threatened legal actions that, in management's opinion, are expected to have a material adverse effect on the company's financial position, results of operations, or cash flows.

Related Party Transactions

• Compensation for Giorgio R. Saumat (CEO) and Mario G. Tabraue (COO) is paid to their respective solely owned LLCs, Point96 Consulting, LLC and Tabraue Consulting, LLC. These entities are considered related parties due to ownership and control relationships.

Stakeholder Impact

• Shareholders: Experienced a significant decrease in earnings per share, potentially impacting investor confidence despite revenue growth and strategic acquisitions. The ongoing share repurchase program could provide some support.
• Employees: Salaries expense increased, indicating potential growth in workforce or compensation, which could be positive for employee morale and retention.
• Customers: Expansion of services (telemedicine, new pharmacy locations, veterinary market) and product lines aims to benefit customers by increasing accessibility and variety of offerings.
• Creditors: Increased total liabilities and a decrease in cash from operations might be a point of scrutiny, though the company's total assets and equity have grown.

Next Steps

• Continue active pursuit of licensure in remaining U.S. states for RxCompound and Mister Meds pharmacies.
• Further development of the MyOnlineConsultation.com healthcare provider network.
• Expansion of MagneChef's product line to include new offerings incorporating its intellectual property.
• Evaluation and recognition of adjustments related to the Taxpayer Fairness and Growth Act of 2025 in future financial statements.
• Continued process improvement changes in internal control over financial reporting.

Key Dates

Recommendation

While Earth Science Tech is pursuing an aggressive growth strategy through acquisitions and market expansion, evidenced by increased revenue and assets, the significant decline in net income and gross margin, coupled with a substantial increase in operating expenses and reduced cash from operations, raises concerns about the profitability and efficiency of this growth. The high executive compensation structure, tied to revenue and asset growth rather than net income, is also a notable factor. Given the mixed financial signals—growth in top-line and assets versus a sharp decline in profitability and cash generation—a 'Hold' recommendation is appropriate. Investors should monitor future quarters for signs of improved operational efficiency and a return to stronger profitability as the acquired businesses are integrated and scaled.

Keywords

Health and Wellness, Compounding Pharmacy, Telemedicine, Real Estate Development, Acquisitions, Pharmaceutical Products, Healthcare, SEC Filing, Quarterly Report, ETST